No recent analyst price targets found for CSPCY.
Latest News for CSPCY
AstraZeneca obesity tie-up with CSPC seen as shrewd move
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) licensing deal on Friday signals a plausible effort by the FTSE 100 group to grab a piece of a booming market for obesity treatments, analysts said, with still plenty to go far despite the market currently being dominated by rivals Novo Nordisk and Eli Lilly. The pharmaceutical group agreed to pay China's CSPC Pharmaceuticals $1.2 billion upfront, with a further $3.5 billion…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CSPCY.
Senate Trading
No Senate trades found for CSPCY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.